复合型右肺大细胞神经内分泌癌1例并文献复习

摘要/Abstract

摘要： 目的：提高对肺大细胞神经内分泌癌(large cell neuroendocrine carcinoma， LCNEC)的临床特点及诊疗手段的认识，减少临床误诊漏诊。方法：对我科确诊的1例肺大细胞神经内分泌癌患者的临床资料进行回顾性分析，并进行文献复习。结果：肺大细胞神经内分泌癌大多数缺乏特征性临床表现，常表现为咳嗽、咳痰、胸痛、咯血等。本患者经彩超引导下肺穿刺活检确诊，随后进行手术治疗，术后病理再次证实。结论：肺大细胞神经内分泌癌临床罕见，确诊需要依靠病理标本结合免疫组织化学指标的联合判断，非转移性的LCNEC建议行手术切除。

关键词: font-size:medium, ">肺大细胞神经内分泌癌；诊断；治疗

Abstract: Objective： To improve the correct diagnosis of pulmonary large cell neuroendocrine carcinoma (LCNEC) in order to reduce misdiagnosis and missed diagnosis rates．Methods： The clinical data of one case of pulmonary LCNEC patient in our hospital was retrospectively analyzed and the correlative literatures were reviewed. Results： Most of pulmonary LCNEC characteristic clinical manifestations， and most manifest in repeated cough， sputum， chest pain， hemoptysis etc. The patient was diagnosed with a lung biopsy guided by color Doppler ultrasound， followed by surgical treatment， and postoperative pathology confirmed again. Conclusion： Pulmonary LCNEC is rare in clinic. The diagnosis depends on the combined judgment of pathological specimens and immunohistochemical indicators. Non-metastatic LCNEC is recommended for surgical resection.

Key words: font-size:medium, ">Pulmonary large cell neuroendocrine carcinoma； Diagnosis； Treatment

中图分类号:

刘大锐, 李报春. 复合型右肺大细胞神经内分泌癌1例并文献复习[J]. 中国医药导刊, 2020, 22(9): 627-630.

LIU Darui, LI Baochun. Large Cell Neuroendocrine Carcinoma of the Right Lung：A Case Report and Literature Review[J]. CHINESE JOURNAL OF MEDICINAL GUIDE, 2020, 22(9): 627-630.

参考文献

[1]Coleman N， Wotherspoon A， Yousaf N， et al. Transformation to neuroendocrine carcinoma as a resistance mechanism to lorlatinib[J]. Lung Cancer， 2019， 134(8)：117-120.
     [2]Morena F， Carminia MDC， Federica P， et al. Pulmonary largecell neurocndocrine carcinoma： from epidemiology to therapy[J]. Journal of Thoracic Oncology， 2015，10(8)：1133.
     [3]Miyoshi T， Umemura S， Matsumura Y， et al. Genomic profiling of large-cell neuroendocrine carcinoma of the lung[J]. Clin Cancer Resear. 2016， 23(3)：757-765.
     [4]Zhuo M， Guan Y， Yang X， et al. The prognostic and therapeutic role of genomic subtyping by sequencing tumor or cell-free DNA in pulmonary large-cell neuroendocrine carcinoma[J]. Clin Cancer Res， 2020，26(4)：892-901.
     [5]Kim HS， Lee JH， Nam SJ， et al. Association of PD-L1 expression with tumor-infiltrating immune cells and mutation burden in high-grade neuroendocrine carcinoma of the lung[J]. Thora Oncol. 2018.13(5)：636-648.
     [6]Lee KW， Lee Y， Oh SW， et al. Large cell neuroendocrine carcinoma of the lung： CT and FDG PET findings[J]．European Journal of Radiologym，2015，84(11)：2332-2338.
     [7]Travis WD, Brambitta E, Muller-Hermelink HK. Pathology and genetics of tumours of the lung, pleura, thymus and heart (WHO classification of tumours)[M]. lyon: IARC Press ,2004: 245-247.
     [8]Roesel C， Terjung S， Weinreich G， et al. A single-institution analysis of the surgical management of pulmonary large cell neuroendocrine carcinomas[J]. Ann Thorac Surg， 2016，101(5)：1909-1914.
     [9]Naidoo J， Santos- Zabala ML， Iyriboz T， et al. Large cell neuroendocrine carcinoma of the lung： clinico-pathologic features， treatment，and outcomes[J]．Clin Lung Cancer， 2016， 17(5)：e121-e129.
     [10]Tsuruoka K， Horinouchi H， Goto Y， et al. PD- L1 expression in neuroendocrine tumors of the lung[J]. Lung Cancer， 2017，108（6）：115-120.
     [11]Karlsson A，Brunnstrom H， Lindquist KE， et al. Mutational and gene fusion analyses of primary large cell and large cell neuroendocrine lung cancer[J]．Oncotarget， 2015， 6(26)：22028- 22037.
     [12]Wincewicz A， Kowalik A， Zieba S， et al. Morphology with immunohistochemical and genetic profiling of high-grade neuroendocrine carcinoma of colon-a case report with review of literature[J]. J Morphol Embryol 2017；58(2)：655-663.
     [13]Hendifar AE， Marchevsky AM， Tuli R， et al. Neuroendocrine tumors of the lung： current challenges and advances in the diagnosis and management of well-differentiated disease[J]. J Thorac Oncol， 2016， 12(3)：425-436.
     [14]Kujtan L， Muthukumar V， Kennedy KF， et al. The role of systemic therapy in the management of stage I large cell neuroendocrine carcinoma of the lung[J]. J Thorac Oncol，2018， 13(5)：707-714.
     [15]Travis WD， Brambilla E， Burke AP， et al. Introduction to The 2015 World Health Organization Classification of Tumors of the Lung， Pleura， Thymus， and Heart[J]．J Thorac Oncol， 2015，10(9)：1240-1242.
     [16]Dincer HE， Podgaetz E， Andrade RS， et al. Pulmonary neuroendocrine tumors： Spectrum and characteristics of tumors[J]．J Bronchology Interv Pulmonol， 2015，22(3)：267-269.
     [17]Drilon A， Laetsch TW， Kummar S， et al. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children[J]. New Engl J Med， 2018，378(8)：731-739.
     [18]Hiroshima K， Mino-Kenudson M. Update on large cell neuroendocrine carcinoma[J]. Transl Lung Cancer Res， 2017， 6(5)：530-539.
     [19]Yamazaki S， Sekine I， Matsuno Y， et al. Clinical responses of large cell neuroendocrine carcinoma of the lung to cisplatin-based chemotherapy[J]. Lung Cancer， 2005，49(2)：217-223.
     [20]Fujiwara Y， Sekine I， Tsuta K， et al. Effect of platinum combined with irinotecan or paclitaxel against large cell neuroendocrine carcinoma of the lung[J]. Jpn J Clin Oncol， 2007， 37(7)：482-486.
     [21]Zhang JT， Li Y， Yan LX， et al. Disparity in clinical outcomes between pure and combined pulmonary large-cell neuroendocrine carcinoma： A multi-center retrospective study[J]. Lung Cancer， 2020，139：118-123.

快速检索引用检索图表检索高级检索